The Efficacy of Additional Motor Training Dosage During the Early Stages Post Stroke on the Upper Extremity Recovery

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAdi Negev-Nahalat Eran

About this trial

Intervention abstract

Background: Stroke is the leading cause of long-term disability, and the second leading cause of death in the western world. Most stroke survivors will suffer from motor and cognitive disturbances for the rest of their life, which negatively affects their normal daily life.

Despite the decline in stroke-related mortality over the past decades, the outcome of rehabilitation programs does not improve, and is predictable regardless of the program used. Still, several human and animal studies show that high capacity of training in the early stages post stroke improve motor recovery. This notion is far from being well established.

Aim: Studying the effect of high-dosage, high-intensity training program in the subacute period on upper extremity motor recovery.

Population: Stroke survivors. Study duration: 6 months. Study protocol: Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks. They will be monitored pre and post training, and 6 months post-stroke. Outcome measures will include clinical, kinematic and adherence measures (see complete list in the protocol).

Eligibility criteria

Qualifiers

Age ≥18 years

Ischemic or hemorrhagic stroke (hemispheric or brainstem) confirmed by CT or MRI

First-ever stroke or previous stroke with no upper extremity weakness

1 week ≤ Time after stroke onset ≤ 6 weeks

Disqualifiers

A painful shoulder limiting an active forward reach

Severe spasticity or non-neural loss of range of motion

Cognitive or communication impairments as determined by the clinical team Unstable medical conditions

Trial design

Treatments tested in this trial

  • High dosage, high intensity motor rehabilitation

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Adi Negev-Nahalat Eran

Lead sponsor

Ben-Gurion University of the Negev

Collaborator